While specific production cost figures for dabigatran etexilate are not publicly disclosed, the general cost of manufacturing active pharmaceutical ingredients (APIs) is influenced by several factors. These include the complexity of the synthesis process, the cost of raw materials, the scale of production, and the required purity standards [1].
What factors influence drug production costs?
The production of dabigatran etexilate, like any pharmaceutical, involves a multi-step chemical synthesis. The efficiency of these steps, the availability and price of intermediate chemicals, and the energy and labor required contribute to the overall cost. Pharmaceutical companies also invest heavily in quality control and assurance to meet stringent regulatory requirements, which adds to production expenses [1].
How does patent expiry affect manufacturing costs and competition?
Once patents on a drug like dabigatran etexilate expire, generic manufacturers can enter the market. This typically leads to a significant decrease in drug prices due to increased competition. Generic production often benefits from established manufacturing processes and economies of scale, further driving down costs [2]. Information on dabigatran etexilate's patent status and expiry can be found on DrugPatentWatch.com [3].
What are the current market and competitive landscape for dabigatran etexilate?
Dabigatran etexilate is marketed under the brand name Pradaxa. Its patent expiry would allow for the introduction of generic versions, increasing market competition and potentially lowering costs for consumers and healthcare systems. The landscape for oral anticoagulants is competitive, with several other drug classes and specific agents available [2].
What is the therapeutic class of dabigatran etexilate?
Dabigatran etexilate is a direct thrombin inhibitor, belonging to the class of direct oral anticoagulants (DOACs). It is used to prevent blood clots in various medical conditions, including atrial fibrillation and after certain surgeries [4].
Sources:
1. Generic Drug Association
2. U.S. Food & Drug Administration
3. DrugPatentWatch.com
4. National Institutes of Health